Stephanie Woodall

Stephanie Woodall currently serves as Quality Site Head at CRISPR Therapeutics, a position held since December 2024. Prior experience includes roles at Abata Therapeutics, where Stephanie progressed from Senior Director to Vice President of Regulatory and Quality from February 2023 to December 2024. At KSQ Therapeutics, Inc., Stephanie held the position of Director, Head of Quality, from August 2019 to January 2023, among other roles. Earlier in Stephanie's career, positions included Senior Manager, QC at Verastem Oncology, Manager, QC and QA at Histogenics Corporation, and QC Biochemist I at Siemens Healthcare. Stephanie began their career in quality control and assurance at bluebird bio and has educational credentials including a B.S. in Biology from the University of Massachusetts Amherst.